Open Orphan has announced that it has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled hRV antiviral product using the hVIVO Asthma Human Challenge Study Model. The study is expected to commence in H1 2022 with revenue to be recognised across 2021 and 2022 and continues to demonstrate the increasing value and breadth of challenge study contracts that the Group is pursuing and winning. In our view, the stock's sharp pullback in recent months represents a str ....
24 Aug 2021
Open Orphan* - New Large Asthma Challenge Study Contract
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - New Large Asthma Challenge Study Contract
hVIVO plc (HVO:LON) | 26.4 -0.2 (-3.3%) | Mkt Cap: 179.3m
- Published:
24 Aug 2021 -
Author:
Andrew Simms -
Pages:
5
Open Orphan has announced that it has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled hRV antiviral product using the hVIVO Asthma Human Challenge Study Model. The study is expected to commence in H1 2022 with revenue to be recognised across 2021 and 2022 and continues to demonstrate the increasing value and breadth of challenge study contracts that the Group is pursuing and winning. In our view, the stock's sharp pullback in recent months represents a str ....